Long COVID After Bamlanivimab Treatment.

Abstract

BACKGROUND:

Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.

METHODS:

Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.

RESULTS:

Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.

CONCLUSIONS:

Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.

CLINICAL TRIALS REGISTRATION:

NCT04518410.

• Authors: Teresa H Evering, Carlee B Moser, Nikolaus Jilg, Eunice Yeh, Busola Sanusi, David A Wohl, Eric S Daar, Jonathan Z Li, Paul Klekotka, Arzhang Cyrus Javan, Joseph J Eron, Judith S Currier, Michael D Hughes, Davey M Smith, Kara W Chew, ACTIV-2/A5401 Study Team
• Journal: The Journal of infectious diseases (J Infect Dis) Vol. 228 Issue Suppl 2 Pg. S126-S135 (08 31 2023) ISSN: 1537-6613 [Electronic] United States
• PMID: 37650236 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural)
• Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• bamlanivimab

Topics

• Female
• Humans
• Male
• Middle Aged
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized (adverse effects)
• COVID-19
• Post-Acute COVID-19 Syndrome